EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives

Putri Cahaya Situmorang, Cheryl Grace Pratiwi Rumahorbo, Leo Jumadi Simanjuntak, Rony Abdi Syahputra iD, Javad Sharifi-Rad iD, Daniela Calina iD

Cell Biology International · 2026

DOI: 10.1002/cbin.70145 ↗

At a glance

Übersichtsarbeit in Cell Biology International, 2026. Written by Putri Cahaya Situmorang and 5 co-authors. Institution: Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, North Sumatra, Indonesia. Major MEDLINE topics: Glucosides, Stilbenes, Neoplasms, Antineoplastic Agents. Cited 2 times so far (Crossref); 132 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cancer remains one of the leading causes of death worldwide, with conventional treatments often facing limitations such as toxicity, drug resistance, and reduced effectiveness over time. Polydatin (PD), a natural glycosylated derivative of resveratrol, has emerged as a promising therapeutic compound due to its ability to induce apoptosis, regulate the cell cycle, modulate oxidative stress, and inhibit angiogenesis. Additionally, PD plays a key role in shaping the tumor microenvironment and enhancing immune responses, making it a strong candidate for use alongside chemotherapy and radiotherapy. This review examines PD's pharmacological potential, highlighting its anticancer mechanisms, therapeutic combinations, and clinical relevance. A systematic literature search was conducted using PubMed, Scopus and Web of Science to analyze preclinical and clinical studies published between 2010 and 2024. Findings suggest that PD enhances chemotherapy efficacy, increases tumor sensitivity to radiotherapy, and reduces drug resistance by targeting critical signaling pathways, including phosphoinositide 3‐kinase/protein kinase B (PI3K/Akt), nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) and mitogen‐activated protein kinase (MAPK). Beyond cancer treatment, PD has demonstrated cardioprotective, neuroprotective, and hepatoprotective properties, further supporting its clinical potential. Despite encouraging preclinical evidence, clinical studies on PD remain limited, emphasizing the need for further investigations into its pharmacokinetics, bioavailability, and safety. Moving forward, research should focus on improving drug delivery systems, conducting rigorous clinical trials, and exploring PD's role in precision medicine to maximize its therapeutic impact in oncology and beyond.

Subjects

MeSH terms (MEDLINE)

GlucosidesStilbenesNeoplasmsAntineoplastic AgentsHumansAnimalsApoptosisTumor MicroenvironmentSignal TransductionOxidative Stress

Author keywords

Polydatinadjuvant cancer therapyapoptosischemotherapy enhancementoxidative stresstumor microenvironment

Substances

polydatinGlucosidesStilbenesAntineoplastic Agents

Authors and institutions

  • Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, North Sumatra, Indonesia.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas HKBP Nommensen, Medan, North Sumatra, Indonesia.
  • Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, North Sumatra, Indonesia.
  • Universidad Espíritu Santo, Samborondón, Ecuador.
  • Department of Medicine, College of Medicine, Korea University, Seoul, South Korea.
  • Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.

ORCID profiles: Rony Abdi Syahputra, Javad Sharifi-Rad, Daniela Calina

Cite

APA

Situmorang, P. C., Rumahorbo, C. G. P., Simanjuntak, L. J., Syahputra, R. A., Sharifi-Rad, J., & Calina, D. (2026). Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives. Cell Biology International. https://doi.org/10.1002/cbin.70145

Vancouver

Situmorang PC, Rumahorbo CGP, Simanjuntak LJ, Syahputra RA, Sharifi-Rad J, Calina D. Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives. Cell Biology International. 2026. doi:10.1002/cbin.70145

BibTeX
@article{Situmorang2026,
  author = {Situmorang, Putri Cahaya and Rumahorbo, Cheryl Grace Pratiwi and Simanjuntak, Leo Jumadi and Syahputra, Rony Abdi and Sharifi-Rad, Javad and Calina, Daniela},
  title = {Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives},
  journal = {Cell Biology International},
  year = {2026},
  doi = {10.1002/cbin.70145}
}
Start for free →